MARKET

MESO

MESO

Mesoblast
NASDAQ
7.28
-0.01
-0.14%
After Hours: 6.76 -0.52 -7.14% 17:14 06/14 EDT
OPEN
7.24
PREV CLOSE
7.29
HIGH
7.32
LOW
7.01
VOLUME
98.62K
TURNOVER
0
52 WEEK HIGH
10.24
52 WEEK LOW
1.610
MARKET CAP
830.44M
P/E (TTM)
-5.0412
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MESO last week (0603-0607)?
Weekly Report · 5d ago
Cantor Fitzgerald Reiterates Overweight on Mesoblast
Benzinga · 06/04 17:22
Mesoblast Eyes FDA Approval and Extends Patent Portfolio
TipRanks · 06/04 10:59
Weekly Report: what happened at MESO last week (0527-0531)?
Weekly Report · 06/03 09:04
Mesoblast Corporate Presentation at Investor Conference
Barchart · 06/02 19:23
Weekly Report: what happened at MESO last week (0520-0524)?
Weekly Report · 05/27 09:04
XPeng Posts Strong Results, Joins Larimar Therapeutics, Transcat And Other Big Stocks Moving Higher On Tuesday
Shares of XPeng Inc. Rose sharply after the company reported better-than-expected first-quarter results and issued second-quarter guidance. Dow Jones index gained around 50 points on Tuesday. Other big stocks recording gains include Nikola Corporation, Transcat, Bloom Energy and Nukkleus.
Benzinga · 05/21 14:38
Weekly Report: what happened at MESO last week (0513-0517)?
Weekly Report · 05/20 09:03
More
About MESO
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.